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Abstract: Increasingly, biobanks are being developed to support organized collections of biological
specimens and associated clinical information on broadly consented, diverse patient populations.
We describe the implementation of a pediatric biobank, comprised of a fully-informed patient cohort
linking specimens to phenotypic data derived from electronic health records (EHR). The Biobank
was launched after multiple stakeholders’ input and implemented initially in a pilot phase before
hospital-wide expansion in 2016. In-person informed consent is obtained from all participants
enrolling in the Biobank and provides permission to: (1) access EHR data for research; (2) collect and
use residual specimens produced as by-products of routine care; and (3) share de-identified data and
specimens outside of the institution. Participants are recruited throughout the hospital, across diverse
clinical settings. We have enrolled 4900 patients to date, and 41% of these have an associated blood
sample for DNA processing. Current efforts are focused on aligning the Biobank with other ongoing
research efforts at our institution and extending our electronic consenting system to support remote
enrollment. A number of pediatric-specific challenges and opportunities is reviewed, including the
need to re-consent patients when they reach 18 years of age, the ability to enroll family members
accompanying patients and alignment with disease-specific research efforts at our institution and
other pediatric centers to increase cohort sizes, particularly for rare diseases.
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1. Introduction
The last two decades have seen a remarkable increase in the establishment of biobanks, especially
those facilitating a broad research agenda across diseases, treatments and outcomes [1]. The mission
and organization of these biobanks vary widely in numbers and types of specimens stored, patient
populations targeted and the availability of linked clinical data from electronic medical records [1,2].
What many share, however, is the potential to advance our understanding of the genetic basis of
disease and to support translational research studies and the development of diagnostic and therapeutic
approaches personalized to individual patients, including children [3,4].
Pediatric-focused biobanks represent a particularly rich opportunity, but they face unique
challenges including rarity of conditions and logistical and regulatory barriers to recruitment of
children into research studies [5,6]. Large pediatric study populations can be efficiently assembled
through biobanks and used to study rare diseases, pediatric-specific disease markers and responses
to treatment and longitudinal clinical phenotypes. However, most United States (U.S.) biobanks
enroll exclusively adult participants, with only 44% including any children and 2% focused entirely
on pediatric patients [1]. A number of pediatric biobanks has been established, including at Boston
Children’s Hospital. In an effort to further inform the advancement of pediatric biobanks and provide
guidance to other institutions developing this resource, we describe here our institutional biobank,
including basic organizational features, challenges and opportunities identified and comparison to a
sampling of other U.S.-based pediatric biobanks.
2. Development and Launch
The Precision Link Biobank at Boston Children’s Hospital (“Biobank”) was established after
extensive consultation and close partnership with a number of stakeholders at our institution.
Input was solicited from investigators, the Institutional Review Board (IRB), research strategy
committees, clinical governance committees, division chiefs and a patient family advisory committee,
among others. It is structured as a research protocol and was approved by the Institutional Review
Board at Boston Children’s Hospital. The Biobank was gradually phased in, operating initially as a
pilot project in a limited number of clinical settings with particular interest in patient participation
in the Biobank, before launching hospital-wide in 2016. Throughout the pilot phase, all patient
encounters were carefully recorded and monitored, including outcomes of conversations with research
assistants and reasons for decline. Based on the positive reception by patients, families, clinical staff
and investigators, recruitment was expanded to additional clinical settings and enrollment models
throughout the hospital.
3. Enrollment via Informed Consent
All patients at Boston Children’s Hospital are eligible for enrollment in the Biobank.
Research assistants obtain informed consent for all participants, and the consent form is signed
by a legal guardian for participants under 18 years of age (Supplementary Materials: informed consent
document). Participants who are 13 to 17 years of age are asked to provide assent by also signing
the form after a verbal discussion. Particular attention is given to the discussion of how we handle
personal health information, or identifiable data, which includes participant name, medical record
number, date of birth and certain other dates. The informed consent process is performed using an
electronic consenting system administered on tablets that are handed to patients. The electronic system
presents a digital version of the consent document, enhanced with an introductory video, pop-up
glossary terms and a feature to highlight areas requiring clarification.
The consent gives permission for the following:
i. Research use of electronic health record (EHR) data. EHR data available for study include
participant demographics, dates and types of encounters (e.g., emergency department (ED) visit,
hospitalization), clinic and hospital discharge notes, diagnoses, laboratory orders and values,
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physical exam findings, medications prescribed and procedures performed. Boston Children’s
Hospital researchers may request the use of identifiable data after a separate approval has been
obtained from the IRB.
ii. Research use of residual specimens collected in the process of routine clinical care.
This encompasses all bodily fluids and tissues, including blood, plasma, cerebrospinal fluid,
urine, fecal samples, buccal swabs, biopsies, aspirates and tissue specimens from any organ
that are no longer needed for the clinical care of a patient.
iii. Sharing of de-identified clinical data and specimens outside of the institution. This may occur
in the form of collaborations with investigators at other medical centers, deposits to central
National Institute of Health repositories (e.g., the database of Genotypes and Phenotypes
(dbGaP)) and partnerships with pharmaceutical companies.
iv. Ongoing data collection. Any clinical data available in the EHR and specimens available at the
time of consent become available to the Biobank. In addition, the Biobank may collect and use
additional data and specimens prospectively until the participant turns 18 years old, at which
time participants can re-enroll as adults.
v. Re-contact for additional data and/or participation in clinical studies. Participants allow the
Biobank to contact them to obtain additional health information, to request additional samples
and to inform them of eligibility for specific research studies.
vi. Broad range of research activities. The types of research activities that may be conducted using data
and specimens from the Biobank include genetic analyses, creation of immortalized cell lines and
pluripotent stem cells, biomarker analyses and epidemiological and outcomes studies. This research
may focus on any disease, condition or treatment, regardless of the participant’s clinical history.
In addition, participants are given the opportunity to consent to the provision of a 4-mL blood
sample for research use. This sample is not required for enrollment in the Biobank. The sample may be
drawn in conjunction with other scheduled clinical tests.
Once a participant turns 18 years of age, she/he must re-consent as an adult to allow for continued
data and sample collection. All information collected up to her/his 18th birthday may continue to be used
under the original consent unless she/he withdraws from the study. Participants are able to withdraw at
any time in which case samples and data are not used for any future research studies, though research on
data and specimens distributed to investigators prior to the withdrawal request may continue.
4. Recruitment Approaches in Different Clinical Settings
Dedicated research assistants enroll participants in-person in clinical settings throughout the
hospital, including outpatient clinics, inpatient units, the ED and general waiting areas, such as in
phlebotomy or radiology. Initially, patients were identified prior to clinical visits whenever possible
and provided with an informational mailing about the Biobank, but we found that this did not have a
substantial impact on knowledge at the time of the encounter with Biobank staff (e.g., few recalled
receiving the information), and thus, pre-contact was discontinued. In each of the clinical settings,
research assistants work closely with clinical staff to tailor enrollment procedures to the clinic workflow
and ensure minimal disruptions in clinical proceedings (e.g., approach patients in the waiting area vs.
in the examination rooms). They also coordinate with other research staff recruiting in the clinics in
order to ensure that patients are not approached more than once during any clinical encounter.
The consent and enrollment process typically takes less than 15 min and is conducted in the
waiting room, clinical examination rooms or, when available, dedicated research enrollment areas.
Research assistants explain the key provisions of the Biobank and ask patients and their families or legal
guardians to review the written informed consent documents. Our research staff answer any questions
that arise and guide participants through the varying levels of participation, including the option to
have a dedicated research blood draw. The consent is currently available in four languages: English,
Spanish, Portuguese and Arabic. For all non-English participants, the informed consent process is
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completed with the assistance of a trained hospital interpreter. In addition, hospital interpreter services
are available to translate the consent into other additional languages as needed.
Patients can choose to enroll, decline or to defer a decision, in which case they are considered
“undecided”. Every interaction and outcome with potential participants is tracked in our research
database. Patients who decline may be approached once more no less than six months later and, if
they decline again, are not approached again. Patients who are undecided may be approached a total
of five times, with no less than seven days between interactions. If they remain undecided, they will
no longer be approached, but are free to contact us in the future to enroll or to decline participation.
Certain clinical settings have dedicated research staff that conduct and manage all patient
recruitment and enrollment to research studies. In these settings, we provide training to the local
research assistants who assume responsibility for enrollment to the Biobank. This offers a number of
advantages, as this research staff is most familiar with the optimal approaches to engage with families
in their clinics and navigate the clinical workflow. Each of these research personnel is first trained by
the Biobank staff and then paired with a Biobank staff member who is available to field questions and
manage data coordination with our Biobank systems.
A number of physician investigators have elected to enroll their own patients in order to build a
cohort of specific patient populations in the Biobank for future study. Examples include patients with
sickle cell anemia and non-alcoholic fatty liver disease. In these cases, a training session is conducted
with the physicians to orient them to the details of the Biobank, the consent process and the information
that must be collected at the time of enrollment. Research assistants remain in close contact with the
physician investigators to facilitate enrollment and manage all participant-tracking procedures.
5. Use of “Merged” Consent Forms
In an effort to align the Biobank with other research studies that involve sample collection at our
institution and create efficiencies through a centralized, shared resource, we have designed an approach
to merge our protocol and consent with existing studies. Through close collaboration with investigators
leading disease-specific specimen repositories at Boston Children’s Hospital, we have created “merged”
consent forms in which participants consent to enrollment in both the Biobank and the investigator’s
specific study through one enrollment encounter and consent form. This merged consent option is
available to any investigator interested in leveraging the resources of the biobank for their studies.
In this case, participants consent to the standard elements of the Biobank, including research use of
health data and discarded specimens, as well as any specific data and sample requirements under
the disease-specific protocol. The research blood draw is generally not optional in this case, as it
is a required feature of many other repositories, which do not rely on discarded specimens and
require the sample for genetic analysis. This sample is collected by the Biobank where it is available
to the specific investigator, as well as to other researchers at the institution. Through consent to
the specific investigator protocol, additional health information, laboratory and clinical testing and
sample collection may be performed, as outlined in the investigator’s protocol. These processes occur
independent of the Biobank, though the information and results may be included in the participant’s
Biobank record and thereby made available to other researchers at the institution.
6. Sample Collection and Management by the Biobank
For participants who consent to the research blood draw, the Biobank collects a 4-mL blood sample
collected in an EDTA tube. This sample is collected by phlebotomists or nurses using a research laboratory
order that is placed in the participant’s EHR. The samples are sent to our central clinical laboratory
from where they are routed to the Biobank for processing and storage. The Biobank can also collect
saliva specimens, where participants unable to provide a blood sample may give a saliva sample instead.
These samples are delivered or sent directly to the Biobank after collection using saliva collection kits.
Protocols employing a merged consent frequently require other types of research samples, such
as blood for serum analysis, stool samples or urine samples for analyses specific to their protocol.
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The Biobank can place research orders in the EHR for these to be collected and sent to the Biobank by
the central clinical laboratory or research staff.
In addition to these research samples, the Biobank may collect all residual clinical specimens for
consented patients at the conclusion of the clinical embargo. This embargo period ensures that all
clinical work can be completed prior to sample distribution for research purposes. The length of this
embargo period varies for different types of samples, ranging from seven days for blood samples to
up to one year for tissue specimens. All residual blood samples drawn in EDTA tubes are identified
through automated reports run in our EHR system and collected by Biobank staff. Multiple residual
samples may be collected until a volume of 10 mL is reached, at which point additional samples are
discarded. Similarly, all pathology specimens for consented patients are deposited in the Biobank.
At this time, other types of specimens are not routinely collected unless an investigator requests a
particular sample type, potentially in a specific patient population, in which case these specimens are
also tagged and become routinely collected. For example, cerebrospinal fluid obtained from patients
in the intensive care unit or urine specimens from patients evaluated for appendicitis in the ED might
be specifically identified, collected and stored.
Specimens are stored and managed by the Biobank Core Lab facility at Boston Children’s Hospital.
This facility handles specimens for a number of different projects and investigators and consists of
2400 square feet of wet lab space and a freezer farm. Each specimen submitted to the Biobank is
verified upon receipt, entered into our laboratory database and assigned a unique ID for accurate
sample tracking and management. The database stores key sample information, including sample
history and chain of custody, as well as phenotypic data and patient demographics. Each freezer is
protected with emergency power, redundant alarm systems and CO2 backup systems.
Biobank specimens are tracked and available for de-identified browsing using a customized
version of the STARLIMS laboratory information management system [7]. In addition to standard
sample metadata, such as data on collection date and quantity, we store specimen-specific metadata
for nucleic acid samples, cells and tissue specimens. The software interfaces with other institutional
informatics systems, including the hospital EHR, to reduce data duplication and maintain specimen,
patient and collection data integrity across systems. Project role-based permission settings are designed
to control access to different features and data.
Research and residual clinical sample collection are integrated into the institutional clinical and
research informatics infrastructure (Figure 1). Research assistants place a laboratory order in the EHR
of consented patients for the sample to be collected. This order triggers a daily notification for sample
pick-up and transport from the clinical laboratory to the Biobank core facility. For residual clinical samples,
our Biobank information system scans the EHR of consented patients and generates a report with sample
and location information for pick-up. Upon pick-up, the whole blood is frozen at −80 ◦C. Samples are
stored indefinitely or until they are released to approved researchers. While not yet our standard operating
procedure, trial runs have indicated that an average of 8 µg can be extracted from 0.5 mL of whole blood.
J. Pers. Med. 2017, 7, 21  5 of 13 
 
Biobank can place research orders in the EHR for these to be c llected and sent to the Biobank by the 
central clinical laboratory or research staff. 
In addition to these research samples, the Biobank may collect all residual clinical specimens for 
consented patients at the conclusion of the clinical embargo. This embargo period ensures that all 
clinical work can be completed prior to sample distribution for research purposes. The length of this 
embargo period varies for different types of samples, ranging from seven days for blood samples to 
up to one year for tissue specimens. All residual blood samples drawn in EDTA tubes are identified 
through automated reports run in our EHR system and collected by Biobank staff. Multiple residual 
samples may be collected until a volume of 10 mL is reached, at which point additional samples are 
discarded. Similarly, all pathology specimens for consented patients are deposited in t  Biobank. At 
his time, other typ s f specimens are not routinely collect d unless an investig tor requests  
particular sample type, potentially in a specific patient population, in which case these specimens are 
also tagged and become routinely collected. For example, cerebrospinal fluid obtained from patients 
in the intensive care unit or urine specimens from patients evaluated for appendicitis in the ED might 
be specifically identified, collected and stored. 
Specimens are stored and managed by the Biobank Core Lab facility at Boston Children’s 
Hospital. This facility handles specimens for a number of different projects and investigators and 
consists of 2400 square feet of wet lab space and a freezer farm. Each specimen submitted to the 
Biobank is verified upon receipt, entered into our laboratory database and assigned a unique ID for 
accurate sample tracking and management. The datab se stores key sample information, in luding 
sample history and chain of custo y, as well s phenotypic data and p tient demographics. Each 
freezer is protected with emergency power, redundant alarm systems and CO2 backup systems. 
Biobank specimens are tracked and available for de-identified browsing using a customized 
version of the STARLIMS laboratory information management system [7]. In addition to standard 
sample metadata, such as data on collection date and quantity, we store specimen-specific metadata 
for nucleic acid samples, cells and tissue specimens. The software interfaces with other institutional 
informatics systems, including the hospital EHR, to reduce data duplication and maintain specimen, 
patient and collection data integrity across systems. Project role-based permission settings are 
designed to control access to different features and data. 
Research and residual clinical sample ti n are integrated into he inst tutional clinical and 
esearch informat cs infrastructure (Figure 1).  as istants place a l boratory order in the EHR 
of consented patients for the sample to be collected. This order triggers a daily notification for sample 
pick-up and transport from the clinical laboratory to the Biobank core facility. For residual clinical 
samples, our Biobank information system scans the EHR of consented patients and generates a report 
with sample and location information for pick-up. Upon pick-up, the whole blood is frozen at −80 °C. 
Samples are stored indefinitely or until they are released to approved researchers. While not yet our 
standard operating procedure, trial runs have indicated that an average of 8 µg can be extracted from 
0.5 mL of whole blood. 
 
Figure 1. Biobank sample workflow. Residual samples are biospecimens that are typically discarded after 
clinical procedures (e.g., blood, tissue, urine). These are collected from all patients enrolled in the Biobank. A 
research sample is a biospecimen collected for research purposes. Participants are given the option to agree to 
this additional sample during the consent process. EHR: electronic health record.  
Figure 1. Biobank sample workflow. Residual samples are biospecimens that are typically discarded
after clinical procedures (e.g., blood, tissue, urine). These are collected from all patients enrolled in the
Biobank. A research sample is a biospecimen collected for research purposes. Participants are given
the option to agree to this additional sample during the consent process. EHR: electronic health record.
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7. Return of Research Results and Patient Privacy
During the consent process, participants are informed that individualized return of results is
not part of the standard procedures of the Biobank. Similarly, results from studies are not added to
the patient medical record or communicated to their physicians. Participants will not be notified if
and/or when their samples are used in a study. Additionally, they are informed that neither they
nor their physician should expect individual results from any study. Participants are made aware
that if there is a result that is determined to be of sufficient medical importance to their child or
themselves, Biobank staff, in consultation with the IRB, may contact the participant directly or through
the participants’ physician, to counsel them about possible result return. Risks of genetic research
and issues of privacy are also reviewed, including protections in place at the federal and institutional
level (e.g., Certificate of Confidentiality) to maintain patient confidentiality and prevent discrimination
based on genetic information.
8. Data Integration, Sample Access and Distribution to Investigators
Biobank consent status, demographic details collected as part of the enrollment process and
basic Biobank specimen characteristics are complemented with phenotypic data automatically derived
from the hospital’s EHR data warehouse, including International Classification of Diseases, Ninth
Revision (ICD-9) encoded diagnoses, laboratory orders and results, radiology orders, procedures
performed, medications administered and prescribed and types of encounters. Data are stored in
an instance of the i2b2/TranSMART open source data analytic platform hosted on Amazon Web
Service (AWS) [8,9]. A Business Associate Agreement between AWS and Boston Children’s Hospital
ensures full compliance with the Health Insurance Portability and Accountability Act. For specimens
undergoing whole exome sequencing, variant call format and Binary Alignment Map (BAM) format
files are stored in i2b2/TranSMART, as well.
Investigators are able to search the Biobank inventory through feasibility queries performed
on de-identified participant data. These searches are performed using i2b2/tranSMART, which
enables investigators to independently identify specific research studies the Biobank can support [10].
For example, an investigator can determine how many participants have been enrolled who have a
diagnosis of asthma, are six years or older, have had at least one hospitalization and have a DNA
sample available in the Biobank.
Use of samples and data is available and free of charge to all Boston Children’s Hospital
investigators. Only investigators based at Boston Children’s Hospital are able to be the primary
requestors of Biobank data and samples. All requests require approval by the Sample and Data
Access Committee, an institutional committee with representation across departments and disciplines.
This entity is charged with reviewing, prioritizing, approving and coordinating requests for use of the
Biobank infrastructure, samples, phenotype data and patient contact options.
Investigators may apply for de-identified or identifiable data, depending on the scientific design
of their study. For de-identified data, investigators apply directly to the Biobank, which acts as an
‘Honest Broker’ [11]. In this case, the Biobank holds the key to the identifiable data, but distributes
only de-identified data and samples to the investigator. If identifiable data are needed (e.g., medical
record number for more detailed phenotype extraction from clinical notes), an IRB-approved protocol
is required that justifies the need for use of personal health information. To date, six requests have
been approved providing data on 225 participants and samples from 69 participants.
Investigators sign a data use agreement prior to sample and data release that outlines the terms
of use and access to the samples and data (Supplementary Materials: data use agreement form).
The recipient investigator agrees, among other terms, to use the data and samples as outlined in the
proposal, to not share the data and samples with any entities beyond what has been set forth in the
proposal and, if identifiable information is to be released, to maintain all participant information as
confidential. In addition, the investigator agrees to inform the Biobank of any sample derivatives at
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the completion of the project, including extracted DNA, cell lines and genetic data files, and to provide
these to the Biobank for future research use, if requested.
Investigators may collaborate with outside entities and share de-identified samples and data.
These collaborations must be outlined in the request submitted to the Biobank Sample and Data Access
Committee and may include partnerships with other academic centers, with research studies based in
for-profit organizations, or with other repositories and research networks.
9. Current Enrollment Status and Participant Characteristics
Since the launch of the Biobank, 4900 patients have enrolled, of which 2750 (56.1%) agreed to
provide a research blood specimen. Currently, we are enrolling over 225 patients per month. Table 1
provides basic demographic and clinical information on these patients.
Table 1. Demographic and clinical information of biobank participants (N = 4900) *.
Mean Age, Years (95% CI) 12.1 (11.8–12.3)
Age Groups, Years
0–1 352 (7.2%)
2–5 1073 (21.9%)
6–11 1182 (24.1%)
12–17 1339 (27.3%)
18+ 954 (19.5%)
Gender
Female 2497 (50.9%)
Male 2395 (48.8%)
Unknown 8 (0.2%)
Race
White 3674 (75.0%)
Black 472 (9.6%)
Asian 168 (3.4%)
Native American/Alaskan Native 9 (0.2%)
Native Hawaiian/Pacific Islander 4 (0.1%)
Other 213 (4.3%)
Prefer not to answer 51 (1.0%)
Unknown 309 (6.3%)
Ethnicity
Non-Hispanic/Latino 3359 (68.6%)
Hispanic/Latino 624 (12.7%)
Prefer not to answer 555 (11.3%)
Unknown 362 (7.4%)
Participants with at least one clinical visit
within the past year 4437 (91.0%)
Surgical encounter 1210 (24.7%)
Admission to Inpatient unit 1099 (22.5%)
Admission to intensive care unit 362 (7.4%)
Most Frequented Clinics (Top 10)
Pre-op Admitting 2650 (54.1%)
Emergency Department 2276 (46.4%)
Outpatient Labs (Phlebotomy) 1968 (40.2%)
Noninvasive Cardiology 1576 (32.2%)
Radiology/Interventional Radiology 1295 (26.4%)
Gastroenterology 1269 (25.9%)
Orthopedics 1217 (24.8%)
Otolaryngology 1153 (23.5%)
Hearing/Speech 870 (17.8%)
Endocrine 865 (17.7%)
* All values represent frequencies and percentages unless otherwise noted.
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For a total of 2009 (41%) participants, we have collected associated blood samples for DNA
processing. Of these, 896 (44.6%) are from research blood samples and 1113 (55.4%) represent residual
blood samples of at least 1 mL. In addition, a total of 221 (4.5%) participants also have tissue specimens
stored in our Biobank.
10. Pediatric-Specific Considerations: Challenges and Opportunities
Several aspects of the enrollment and sample collection process are pediatric-specific. The informed
consent is conducted with parents or legal guardians, though the child may also participate at various
time points. During the enrollment process, participants 13 to 17 years of age are included in the
informed consenting process and asked to provide assent and sign the consent form along with
their parent or legal guardian. When participants reach maturity at 18 years of age, they must be
re-consented to allow ongoing sample collection and access to EHR data recorded after their 18th
birthday. Research on samples and data that have already been distributed may continue. While the
re-consenting process can be challenging as contact information for the participant is not always
available, this process affords the opportunity to re-engage participants, inform them of ongoing
research projects and new ones for which they might be eligible and to collect additional clinical data.
Another unique opportunity emerges in the process of consenting participants through their
parents: we are able to recruit parents and other family members to the Biobank along with the child.
Analyzing sequencing data from trios—the child and her/his biologic parents—enhances capacity to
identify relevant variants, particularly in regions that are not well covered by sequencing platforms,
and the ability to directly observe the inheritance of these variants.
Enrolling sufficiently large cohorts of pediatric patients can be challenging because of the small
number of patients with certain diseases or other specific features. We have taken several approaches
to increase our recruitment and enrollment volume. First, we have aligned our Biobank with
disease-specific research efforts at our institution such that patients may enroll in these disease-specific
studies, while also contributing data to a centralized Biobank. This enables us to expand the enrollment
of certain patient populations and allow their samples and data to be accessed by investigators across
the institution. In addition, we are actively engaged in building a network of pediatric institutions that
will share de-identified sample and clinical data from participants in their respective biobanks [12].
This type of data pooling holds tremendous potential to augment the study of patients with rare
diseases. Finally, in an effort to directly facilitate the enrollment process, we have launched an electronic
consenting system in which participants are able to perform the consenting process independently
using handheld tablets during their clinical visit [13]. Research assistants can engage with multiple
families simultaneously with this approach and remain available to provide assistance and answer
questions. We are currently expanding the electronic consenting platform to support remote consenting,
by which participants can complete the enrollment process without a clinical encounter [14].
Research-specific blood samples are optional in our Biobank as parents may be concerned about
having additional blood drawn during a scheduled clinical test. As a result, we do not have research
blood specimens on all participants. In addition, even among those who do consent to the research
blood draw, pediatric participants typically only provide the research specimen when clinical testing is
required, and this may not occur at every encounter. In order to supplement the research samples, our
Biobank has implemented a tracking system to systematically identify all residual blood specimens for
collection. This system has allowed us to increase the percentage of patients with a viable specimen for
DNA sequencing from 15% to 41%. In addition, it allows us to collect other types of clinical specimens
(e.g., residual biopsy tissue) beyond the research sample.
As an additional approach to increasing specimen data, we are targeting patients for Biobank
enrollment who are having genetic testing (e.g., whole exome sequencing) performed as part of
their clinical evaluation. These patients have sequencing data deposited in their EHR, and Biobank
investigators can access these data through approved protocols. For these participants, research blood
samples are not necessary.
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11. Discussion/Conclusions
Table 2 illustrates selected U.S.-based pediatric biobanks to highlight different approaches in
mission and operational features. While several enroll all eligible participants, some focus on
specific conditions and patient populations. When informed consent is obtained, dedicated research
samples—including blood, urine, saliva, CSF and tissue—are collected, sometimes in addition to residual
clinical samples. All biobanks link at least some clinical data to the samples, though not all include
personal identifiers. Different types of re-contact of participants are supported, including informing
participants of other potential research studies of interest and receiving information on incidental research
findings. All biobanks in this sample also support sharing of samples and data with outside investigators
in collaborative efforts and are able to prospectively collect data beyond the consent date.
We continue to advance the Biobank with new capabilities including computable phenotyping,
electronic consenting and inclusion of additional data types, such as imaging and patient-reported
data. Implementation of an electronic consenting system will support both in-hospital and remote
participant enrollment extending our reach to diverse patient groups that may not be fully represented
in our clinics and inpatient units. In addition, we are expanding our hospital patient portal to include
research functionality for patient contact, data collection and notification of research results.
More than 95% of hospitals have adopted EHRs and increasingly, longitudinal data are becoming
available to support deep phenotyping [15]. These health system data are also more commonly being
complemented by patient reports [16,17]. Hence, there is greater motivation than ever to develop
robust processes to collect broadly consented samples linked to phenotype and available for genomic
and gene expression testing. Accumulating omics-phenotype databases will drive not only discovery,
but also transform care through better characterization of our patients and improved diagnostics [18].
Our efforts are intended to ensure that children benefit from these advances.
J. Pers. Med. 2017, 7, 21 10 of 13
Table 2. Features of selected U.S.-based pediatric biobanks.
Name Institution PatientPopulation Consent Type Sample Types
Medical Record
Data Linked to
Sample?
Identified Data? Re-Contact Type
Able to Share Data
and/or Samples Outside
of Institution?
Prospective Sample
and/or Clinical Data
Collected (i.e., beyond
Consent Date)?
Precision Link
Biobank
Boston Children’s
Hospital All
• Opt-in,
fully-informed consent
• Any research question
• Research blood and
saliva samples
• Residual
clinical samples
Yes Yes
• To receive information
about the Biobank
• To receive requests for
additional data
and samples
• To learn about potential
research studies of interest
• To receive information on
incidental research findings
Yes, de-identified data
with local faculty
member as
co-investigator
Yes
Better Outcomes for
Children [19]
Cincinnati
Children’s
Hospital Medical
Center
All
• Opt-in, using
condensed consent
document presented by
hospital registrar
• Residual
clinical samples
Yes, through
linkage with a
separate
repository with
clinical data
No
• To receive information on
incidental research findings
Yes, de-identified data
with local faculty
member as
co-investigator
Yes
Pediatric BioVU [20]
Vanderbilt
University
Medical Center
All
• Opt-out *
• Any research question
related to health
and wellness
• Residual
clinical samples Yes No • None
Yes, de-identified data
with local faculty
member as
co-investigator
Yes
Pediatric CNS
Biorepository
Children’s
National Health
System
Patients with
neurological
diseases
Different types
of consents:
- opt-in,
fully-informed consent
- waived consent
- post-mortem consent
Any research question
related to
neurological diseases
• Research blood,
saliva, tissue, CSF,
and urine samples
• Residual
clinical samples
Yes, depending
on the type of
consent obtained
Yes, depending
on the type of
consent obtained
Depending on type
of consent:
- To receive requests for
additional data
and samples
- To request to use the data
and samples for other
research studies
Yes, de-identified data Yes
Pediatric Cancer
Genome Project
St. Jude’s
Children’s
Research Hospital
Patients with
oncologic and
hematologic
conditions
• Opt-in,
fully-informed consent
• Any research question
• Research blood
draws and
urine samples
• Residual
clinical samples
Yes Yes
• To receive information
about the biobank
• To receive requests for
additional data
and samples
• To learn about potential
research studies of interest
• To receive information on
incidental research findings
Yes, de-identified data Yes
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Table 2. Cont.
Name Institution PatientPopulation Consent Type Sample Types
Medical Record
Data Linked to
Sample?
Identified Data? Re-Contact Type
Able to Share Data
and/or Samples Outside
of Institution?
Prospective Sample
and/or Clinical Data
Collected (i.e., beyond
Consent Date)?
The Down Syndrome
Achieves Down
Syndrome Biobank
Nationwide
Children’s **
Patients with
Down syndrome
• Opt-in,
fully-informed consent
• Research
blood samples
Yes, annotated with
specific clinical data
Yes, to the
collecting site;
de-identified for
external sharing
• To receive requests for
additional data
and samples
• To learn about potential
research studies of interest
• To receive information on
incidental research findings
No, for the time being
limited to members
within network
No
Children’s Brain
Tissue Research
Consortium
Children’s
Hospital of
Philadelphia **
Patients with
CNS tumors
• Opt-in,
fully-informed consent
• Consent waiver for
deceased patients
• Research
saliva samples
• Residual clinical
tissue, blood, and
CSF samples
Yes, annotated with
specific clinical data
Yes, to the
collecting site;
de-identified for
external sharing
None Yes, de-identified data Yes
* Patients must acknowledge that they are choosing not to opt out; ** institution acts as the coordinating center and manages data and sample storage.
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